Sitaxentan
Sitaxentan sodium (TBC-11251) is a medication for the treatment of pulmonary arterial hypertension (PAH). It was marketed as Thelin by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market due to concerns about liver toxicity.Citing liver damage, Pfizer withdraws Thelin
Associated Press, December 12, 2010

Mechanism of action

Sitaxentan is a

small molecule

that blocks the action of

[...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu]